A phase ii trial of combined chemotherapy and surgery in stage iiia non-small cell lung cancer

详细信息    查看全文

• 作者：Samir Darwish ; Vincenzo Minotti ; Lucio Crinó ; Riccardo Rossetti ; Paolo Fiaschini ; Ernesto Maranzano ; Franco Checcaglini ; Tommaso Todisco ; Michele Giansanti ; Ugo Mercati ; Rino Vitali ; Paolo Latini ; Maurizio Tonat
• 关键词：Non-small cell lung cancer ; Neoadjuvant chemotherapy ; Cisplatin
• 刊名：Lung Cancer
• 出版年：1995
• 出版时间：April 1995
• 年：1995
• 卷：12
• 期：Supplement 1
• 页码：S71-S78
• 全文大小：462 K

文摘

A poor prognosis for patients with Stage IIIA clinical N2 treated by surgery alone has led clinical researchers to find a new treatment modality to improve the curative potential of surgery. Many Phase II trials have been carried out with induction chemo-or chemo-radiotherapy prior to surgery. From June 1988 to July 1991, 46 patients with non-small cell lung cancer (NSCLC) Stage IIIA clinical N2 entered a Phase II induction-chemotherapy trial. Patients received 2–3 cycles of high-dose cisplatin and etoposide. Forty-five were evaluable for response; the response rate was 82 % (37/45: 3 CR, 34 PR). Toxicity was primarily hematologic. Surgical resection was performed in 35 patients; radical resection was possible in 28 patients (62 % ); three patients were incompletely resected and two patients were only explored. Three deaths were surgery-related. Median survival was 24.5 months with a 2-year survival of 53 % . Cisplatin with etoposide is an active and safe induction chemotherapy regimen for NSCLC Stage IIIA N2 with a high response rate. The median survival seems to be prolonged and therefore, randomized trials are needed to compare this approach with other treatment modalities.